Publications by authors named "Reinhard Dummer"

100Publications

Iatrogenic tattoos after acupuncture: successful outcome after treatment with QS Ruby Laser: A case report and review of literature.

Laser Ther 2019 Jun;28(2):139-144

Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5978/islsm.19-CR-01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456649PMC
June 2019

Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.

Oncologist 2020 Sep 4. Epub 2020 Sep 4.

Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0656DOI Listing
September 2020

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

N Engl J Med 2020 09 2;383(12):1139-1148. Epub 2020 Sep 2.

From University Hospital Zurich Skin Cancer Center, Zurich, Switzerland (R.D.); University Hospital Schleswig-Holstein, Kiel (A. Hauschild), University Hospital Essen, Essen (D.S.), and German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute-IRCCS, Padua (V.C.S.) - all in Italy; Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), Alfred Hospital, Melbourne, VIC (A. Haydon), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.) - all in Australia; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Royal Marsden NHS Foundation Trust, London (J.L.), and the Northern Centre for Cancer Care, Freeman Hospital and Newcastle University, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Oslo University Hospital, the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv - both in Israel (J.S.); Novartis Healthcare, Hyderabad, India (K.D.); and Novartis Pharmaceuticals, East Hanover, NJ (E.G., M.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2005493DOI Listing
September 2020

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.

Eur J Cancer 2020 Aug 26;138:68-76. Epub 2020 Aug 26.

University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.07.016DOI Listing
August 2020

Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma.

Front Oncol 2020 7;10:1163. Epub 2020 Aug 7.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.01163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426470PMC
August 2020

Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma.

J Clin Med 2020 Aug 20;9(9). Epub 2020 Aug 20.

Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112 Halle, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9092690DOI Listing
August 2020

Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.

ESMO Open 2020 Aug;5(4)

Department of Neurosurgery & Clinical Neuroscience Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2020-000763DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401999PMC
August 2020

Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications.

Cancer Treat Rev 2020 Aug 23;88:102060. Epub 2020 Jun 23.

Unit of Melanoma, Division of Medical Oncology, Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102060DOI Listing
August 2020

Recurrent squamous cell carcinoma of the perianal skin: a case report.

ESMO Open 2020 May;5(3)

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2020-000786DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232630PMC
May 2020

A Monocentric, Retrospective Analysis of 61 Patients with Generalized Granuloma Annulare.

Dermatology 2020 13;236(4):369-374. Epub 2020 May 13.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384347PMC
May 2020

Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.

J Invest Dermatol 2020 May 7. Epub 2020 May 7.

Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2020.02.047DOI Listing
May 2020

The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma.

Histopathology 2020 Sep 4;77(3):460-470. Epub 2020 Jul 4.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.14139DOI Listing
September 2020

Laser Treatment of Accidental Tattoos: Experience at a Tertiary Referral Center.

Dermatology 2020 2;236(4):383-389. Epub 2020 Apr 2.

Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506459DOI Listing
April 2020

Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth.

Oncogene 2020 May 1;39(20):4132-4154. Epub 2020 Apr 1.

Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Wagistrasse 14, 8952, Schlieren, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-020-1267-7DOI Listing
May 2020

Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy.

Am Soc Clin Oncol Educ Book 2020 Mar;40:1-10

Division of Medical Oncology, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_278953DOI Listing
March 2020

Targeting complex, adaptive responses in melanoma therapy.

Cancer Treat Rev 2020 Jun 2;86:101997. Epub 2020 Mar 2.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.101997DOI Listing
June 2020

Evaluation of the minimal erythema dose for UVB and UVA in context of skin phototype and nature of photodermatosis.

Photodermatol Photoimmunol Photomed 2020 May 19;36(3):200-207. Epub 2020 Feb 19.

Department of Dermatology, University Hospital Zurich, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12537DOI Listing
May 2020

Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma.

Oncotarget 2019 Nov 5;10(60):6509-6525. Epub 2019 Nov 5.

Institute of Anatomy and Cell Biology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849650PMC
November 2019

Use of Lasers for Iron-Induced Accidental Tattoos: Experience at a Tertiary Referral Center.

Dermatol Surg 2020 Sep;46(9):1176-1182

All authors are affiliated with the Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DSS.0000000000002262DOI Listing
September 2020

Efficacy and safety of colchicine in inflammatory skin diseases: a retrospective, monocentric study in a large tertiary center.

J Dermatolog Treat 2019 Nov 20:1-6. Epub 2019 Nov 20.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1690621DOI Listing
November 2019

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy.

Acta Derm Venereol 2020 Jan 7;100(1):adv00007. Epub 2020 Jan 7.

Department of Dermatology , University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3355DOI Listing
January 2020

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2019 10 28;381(16):1535-1546. Epub 2019 Sep 28.

From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) - both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital, Siena (M.M.) - all in Italy; the University of Colorado Cancer Center, Aurora (R.G.); Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille Hôpital Timone, Marseille (J.-J.G.), and Université de Paris, INSERM Unité 976, Assistance Publique-Hôpitaux de Paris Dermatology and Centres d'Investigation Clinique, Saint Louis Hospital, Paris (C.L.) - both in France; the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); the University of Michigan, Ann Arbor (C.D.L.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Universitäts Spital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB (M.S.), and the Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.H.), the Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney, Sydney, NSW (M.S.C., G.V.L.), and the Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and the Peter MacCallum Cancer Centre, Melbourne, VIC (G.M.) - all in Australia; General University Hospital Gregorio Marañon and Centro de Investigación Biomédica en Red de Oncología, Madrid (I.M.-R.); the Netherlands Cancer Institute, Amsterdam (J.H.); the Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Leuven, Leuven, Belgium (P.S.); University of California San Diego Health-La Jolla Moores Cancer Center, La Jolla (G.A.D.); the Department of Oncology, Odense University Hospital, Odense, Denmark (L.B.); Bristol-Myers Squibb, Princeton, NJ (J.I.R., A.B., A.M.); Dana-Farber Cancer Institute, Boston (F.S.H.); and the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910836DOI Listing
October 2019

Dapsone in a Large Tertiary Center: Outdated Therapeutic Option or Timeless Agent?

Dermatology 2020 11;236(3):183-190. Epub 2019 Sep 11.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502256DOI Listing
September 2020

How I treat metastatic melanoma.

ESMO Open 2019 21;4(Suppl 2):e000509. Epub 2019 Jul 21.

Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2019-000509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677980PMC
July 2019

Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.

Expert Opin Investig Drugs 2019 Sep 18;28(9):799-809. Epub 2019 Aug 18.

Department of Dermatology, University Hospital of Zurich , Zurich , Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1654995DOI Listing
September 2019

Is single versus combination therapy problematic in the treatment of cutaneous melanoma?

Expert Rev Clin Pharmacol 2020 Mar 19:1-15. Epub 2020 Mar 19.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1650641DOI Listing
March 2020

Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival.

Pigment Cell Melanoma Res 2020 01 8;33(1):74-85. Epub 2019 Aug 8.

Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12812DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972519PMC
January 2020

Radiotherapy in Periocular Cutaneous Malignancies: A Retrospective Study.

Dermatology 2019 2;235(3):234-239. Epub 2019 Apr 2.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496539DOI Listing
December 2019

Reply to E. Hindié and K.R. Hess.

J Clin Oncol 2019 05 2;37(15):1356-1358. Epub 2019 Apr 2.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00004
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00004DOI Listing
May 2019

Serum S100B Levels in Melanoma.

Methods Mol Biol 2019 ;1929:691-700

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-9030-6_43
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-9030-6_43DOI Listing
July 2019

Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.

Eur J Dermatol 2018 Dec;28(6):736-749

Skin Cancer Centre/Dermatology Clinic, Universitätsspital Zürich, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3447DOI Listing
December 2018

Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.

JAMA Oncol 2019 May;5(5):730-731

Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.6431DOI Listing
May 2019

Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation.

Cell Rep 2018 12;25(13):3564-3572.e4

Institute of Experimental Immunology, Department of Inflammation Research, University of Zurich, 8057 Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247183192
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2018.12.012DOI Listing
December 2018

Potassium Iodide for Cutaneous Inflammatory Disorders: A Monocentric, Retrospective Study.

Dermatology 2019 21;235(2):137-143. Epub 2018 Nov 21.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494614DOI Listing
June 2019

A new B-Raf inhibitor combo for advanced melanoma.

Oncotarget 2018 Oct 2;9(77):34457-34458. Epub 2018 Oct 2.

Reinhard Dummer: Department of Dermatology, University Hospital Zurich, Switzerland; University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195377PMC
October 2018

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma.

J Clin Oncol 2018 12 22;36(35):3441-3449. Epub 2018 Oct 22.

Axel Hauschild, University Hospital Schleswig-Holstein, Kiel; Dirk Schadendorf, University Hospital Essen, Essen; German Cancer Consortium, Heidelberg, Germany; Reinhard Dummer, University Hospital Zürich Skin Cancer Center, Zürich; Tomas Haas, Novartis AG, Basel, Switzerland; Mario Santinami, Fondazione Istituto Nazionale Tumori, Milan; Mario Mandalà, Papa Giovanni XXIII Cancer Center Hospital, Bergamo; Vanna Chiarion-Sileni, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy; Victoria Atkinson, Princess Alexandra Hospital; Gallipoli Medical Research Foundation; University of Queensland, Brisbane, Queensland; Andrew Haydon, The Alfred Hospital, Melbourne, Victoria; Richard Kefford, Macquarie University; Westmead Hospital; Richard Kefford and Georgina V. Long, Melanoma Institute Australia; University of Sydney; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; James Larkin, Royal Marsden National Health Service Foundation Trust, London; Ruth Plummer, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Marta Nyakas, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux; Caroline Robert, Institute Gustave Roussy, Paris; Laurent Mortier, Université de Lille, Institut National de la Santé et de la Recherche Médicale U1189, Centre Hospitalier Universitaire de sa Region Lille, Lille; Thierry Lesimple, Centre Eugène Marquis, Rennes, France; Jacob Schachter, Sheba Medical Center, Tel Hashomer; Tel Aviv University, Tel Aviv, Israel; Kohinoor Dasgupta, Novartis Healthcare, Hyderabad, India; Mark Shilkrut and Eduard Gasal, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and John M. Kirkwood, UPMC Hillman Cancer Center; University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01219
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159PMC
December 2018

The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe.

Curr Oncol Rep 2018 09 24;20(11):87. Epub 2018 Sep 24.

Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0732-8
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0732-8DOI Listing
September 2018

Immunological effects of BRAF+MEK inhibition.

Oncoimmunology 2018 23;7(9):e1468955. Epub 2018 Jul 23.

Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1468955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140547PMC
July 2018

EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.

Cancer Cell 2018 07 28;34(1):69-84.e14. Epub 2018 Jun 28.

Stem Cell Biology, Institute of Anatomy, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.06.001DOI Listing
July 2018